Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Athira Pharma, Inc.
Athira Pharma to Participate in Upcoming June Conferences
May 31, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
May 22, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
May 11, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Participate in Upcoming May Investor Conferences
May 08, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 25, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 11, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 28, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
March 23, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
March 08, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
March 06, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
February 01, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
January 31, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Provides 2023 Pipeline Outlook
January 05, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
December 21, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
December 05, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
December 01, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
November 29, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
November 28, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 21, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
November 16, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
November 10, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present at Stifel 2022 Healthcare Conference
November 09, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
November 07, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
October 17, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.